about
Efficacy, safety, and patient acceptability of elvitegravir/cobicistat/emtricitabine/tenofovir in the treatment of HIV/AIDSHIV-1 A1 Subtype Epidemic in Italy Originated from Africa and Eastern Europe and Shows a High Frequency of Transmission Chains Involving Intravenous Drug UsersSwitch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational CohortFour years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E Study.Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis C coinfection: data from the ICONA foundation cohort.Cost per care of the first year of direct antiviral agents in the Liguria Region: a multicenter analysis.Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project.The ligurian human immunodeficiency virus clinical network: a web tool to manage patients with human immunodeficiency virus in primary care and multicenter clinical trials.A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen.96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience.Pharmacokinetics of rifabutin in HIV-infected patients with or without wasting syndrome'Emergency exit' of bone-marrow-resident CD34(+)DNAM-1(bright)CXCR4(+)-committed lymphoid precursors during chronic infection and inflammationIs it still worthwhile to perform quarterly cd4+ t lymphocyte cell counts on hiv-1 infected stable patients?Increasing prevalence of genitourinary schistosomiasis in Europe in the Migrant Era: Neglected no more?Budget impact analysis of sofosbuvir-based regimens for the treatment of HIV/HCV-coinfected patients in northern Italy: a multicenter regional simulationDiscontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized TherapyCandida infections in the intensive care unit: epidemiology, risk factors and therapeutic strategies.Bloodstream infections in HIV-infected patients.Natural killer cells in HIV controller patients express an activated effector phenotype and do not up-regulate NKp44 on IL-2 stimulationMaraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trial.Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study groupVaginal HIV-1 shedding among HIV-1 infected women in the current era of combined antiretroviral therapy: A cross sectional study.Nevirapine-based regimens in routine clinical settings: results from a large Italian cohort of HIV-1 infected adults.Which patients have greatest need for elvitegravir/cobicistat/ emtricitabine/tenofovirDF-based therapy?Bedaquiline: a new hope for shorter and better anti-tuberculosis regimens.Pregnancy and neonatal outcomes among a cohort of HIV-infected women in a large Italian teaching hospital: a 30-year retrospective study.Predictive factors of hyperlipidemia in HIV-infected subjects receiving lopinavir/ritonavir.Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals.Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results.Effectiveness, safety, durability and immune recovery in a retrospective, multicentre, observational cohort of ART-experienced, HIV-1-infected patients receiving maraviroc.Genotypic determination of HIV tropism in a cohort of patients perinatally infected with HIV-1 and exposed to antiretroviral therapy.Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial.The problem of renal function monitoring in patients treated with the novel antiretroviral drugs.Cardiovascular risk and dyslipidemia among persons living with HIV: a review.PrEP in Italy: The time may be ripe but who's paying the bill? A nationwide survey on physicians' attitudes towards using antiretrovirals to prevent HIV infection.Quality of life in an Italian cohort of people living with HIV in the era of combined antiretroviral therapy (Evidence from I.A.N.U.A. study-investigation on antiretroviral therapy).Exophytic Lesion of the Tongue in a Patient with Undetectable HIV-RNA in the Past 3 Years.Effectiveness of first-generation HCV protease inhibitors: does HIV coinfection still play a role?Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides.Commentary: Human Immunodeficiency Virus and Allergic Bronchopulmonary Aspergillosis.
P50
Q26783253-B8506D99-0A0A-4034-AC40-6D98C44E6954Q28552320-3644F6BE-220C-4CB6-AC23-4025E9BCFB41Q28552719-84050468-E5E2-498D-B618-5EA8B34494BFQ30710478-DBADD834-325A-4460-96E7-5CB66E61CC90Q30843946-08A0735C-61B2-4493-B28E-5476915F4A04Q33734454-99F1AB56-EC15-4C68-B004-B6D968FACACDQ33817410-303B0ED9-B361-4BEB-B790-69A2E0A3D2CEQ33855379-9E6A89E1-031E-4FE1-9019-A0A8E29723C5Q33932293-899AB443-CF9F-4AF3-A923-F11FCD6A36E5Q34341541-19A83806-61DE-455D-9510-D2BFA2D6295FQ36053793-6FEEB4AA-B2A9-4F62-9CA6-D14272D3BAEDQ36145878-E58B2C8F-F4CB-44E6-B19F-8D537D9F92E8Q36271973-1E1861C6-6DE2-452D-94D9-EE812D862972Q36310360-1B4365D2-752B-4366-8C77-EF934256E8F1Q36444618-AC6AC4A5-FFD5-46BB-8DE4-F95F5A4C9C2CQ36628396-4D9DAA08-11E8-477A-8741-94625A52901AQ36670916-440C936D-6B93-4147-AF6B-246A131821E3Q36913307-A4524617-B9CC-4650-B99B-FEE96016373FQ37031810-9F3A50D4-F654-47CA-977A-8E8CE6622784Q37308894-E6F7A4CB-5716-4CE5-9D03-E6FD44576A01Q37530942-1DA0DC72-6E2E-4AB1-81CE-D7AF8FDDC4CDQ37705397-ACE4BF1A-99E9-4875-8972-3287AD0A668DQ37961892-6B214D18-8DB0-4FAC-A8DD-F8F08839D16DQ38230316-00718029-1178-4745-AE48-BED37C206BC6Q38669764-266ADEF0-BB7E-4128-99F0-B4471F8A761DQ38889054-CA5A07C8-64BE-46AE-9DDD-716ED59AF2ACQ38914167-994E8D66-2242-4D5D-BE4B-6B67E1B10B4BQ38914178-850FA960-D043-4AA3-A83F-CED357C92980Q38934042-DDDD6445-6839-4E5F-9E4B-14937BDA5EA7Q38970509-8C2CDDB5-479B-4CF3-B2CF-5FD42C56CB43Q38972095-7512DBD9-5994-4A51-BD0C-C8086FADCE4FQ39015984-84958B17-C7CA-4DBB-83A0-3BDB17142CD2Q39203030-CD2F4626-68BD-4AC4-8C4E-6B302FE59C5AQ40100018-697A8815-C82A-44A9-BCD3-65EC14F7ACE7Q40126361-667BFB5F-8DD8-48F4-9B9B-FF0A99C9F8D8Q40354648-B116ACF5-CABF-4CF4-856D-56C52D6602C5Q40415963-5F65DD90-B936-466A-9DAB-75F0F9C6328FQ40439011-8D7BFBC2-F0E7-482F-833D-C20FF2786E7AQ40467061-AB0E68A6-4C71-4C29-9CA0-1C8EF7546BECQ40472357-44851D59-8416-4828-B4EE-6660BDE2837C
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Antonio Di Biagio
@ast
Antonio Di Biagio
@en
Antonio Di Biagio
@es
type
label
Antonio Di Biagio
@ast
Antonio Di Biagio
@en
Antonio Di Biagio
@es
prefLabel
Antonio Di Biagio
@ast
Antonio Di Biagio
@en
Antonio Di Biagio
@es
P106
P1153
6603362308
P21
P31
P3835
antonio-di-biagio
P496
0000-0003-1436-5089